February 10, 2026 02:59 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
‘Won’t allow any impediment in SIR’: Supreme Court pulls up Mamata govt over delay in sharing officers’ details | India-US trade deal: ‘Negotiations always two-way’, says Amul MD amid farmers’ concerns | Khamenei breaks 37-year-old ritual for first time amid escalating Iran-US tensions | India must push for energy independence amid global uncertainty: Vedanta chairman Anil Agarwal | Kanpur horror: Lamborghini driven by businessman’s son rams vehicles, injures six | ‘Namaste Trump beat Howdy Modi’: Congress slams PM Over India-US trade deal | Historic India-US trade pact: Tariffs cut, $500B market opportunity unlocked! | Big call from RBI: Repo rate stays at 5.25%, neutral stance continues | RG Kar scam twist: Court issues non-bailable warrant against whistle-blower Akhtar Ali | Court snub for Vijay: Madras HC rejects plea in ₹1.5 crore tax case
Sputnik V
Wallpaper Cave

Sputnik V vaccine is more efficient against Delta variant of coronavirus: Study

| @indiablooms | Jun 16, 2021, at 12:01 am

Moscow: The Russia-developed Sputnik V vaccine has been found working efficiently against the Delta variant of the COVID-19 disease, a study revealed on Tuesday.

The variant of the disease was first reported from India.

The makers of the vaccine claimed that Sputnik V is working effectively against the variant than any other vaccine that published results on this strain so far.

Sputnik V's official Twitter handle posted: "#SputnikV is more efficient against the Delta variant of coronavirus, first detected in India than any other vaccine that published results on this strain so far - the Gamaleya Center study submitted for publication in an international peer-reviewed journal."

Meanwhile, a new analysis by PHE shows for the first time that 2 doses of COVID-19 vaccines are highly effective against hospitalisation from the Delta (B.1.617.2) variant, Public Health England said on Monday.

The analysis showed the Pfizer-BioNTech vaccine is 96 percent effective against hospitalisation after two doses.

Similarly, the Oxford-AstraZeneca vaccine is 92 percent effective against hospitalisation after 2 doses.

These are comparable with vaccine effectiveness against hospitalisation from the Alpha variant.

 Further work remains underway to establish the level of protection against mortality from the Delta variant. However, as with other variants, this is expected to be high.

The analysis included 14,019 cases of the Delta variant – 166 of whom were hospitalised – between 12 April and 4 June, looking at emergency hospital admissions in England, PHE said in a statement.

Public Health England (PHE) has previously published analysis showing that one dose is 17 percent less effective at preventing symptomatic illness from the Delta variant, compared to Alpha, but there is only a small difference after 2 doses.

Health and Social Care Secretary Matt Hancock said: " This evidence of the effectiveness of two doses against variants shows just how crucial it is to get your second jab."

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.